• 1
    Moodie Z, Janes H, Huang Y. New clinical trial designs for HIV vaccine evaluation. Curr Opin HIV AIDS 2013;8:43641.
  • 2
    Rolland M, Gilbert P. Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide. AIDS Res Hum Retroviruses 2012;28:4004.
  • 3
    Van Regenmortel MH. Basic research in HIV vaccinology is hampered by reductionist thinking. Front Immunol 2012;3:194.
  • 4
    Corey L, Nabel GJ, Dieffenbach C et al. HIV-1 vaccines and adaptive trial designs. Sci Transl Med. 2011;3:79ps13.
  • 5
    McChesney MB, Miller CJ. New directions for HIV vaccine development from animal models. Curr Opin HIV AIDS 2013;8:37681.
  • 6
    Barouch DH, Liu J, Li H et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012;482:8993.
  • 7
    Genovese L, Nebuloni M, Alfano M. Cell-mediated immunity in elite controllers naturally controlling HIV viral load. Front Immunol 2013;4:86.
  • 8
    Jennes W, Sawadogo S, Koblavi-Dème S et al. Cellular human immunodeficiency virus (HIV)-protective factors: a comparison of HIV-exposed seronegative female sex workers and female blood donors in Abidjan, Côte d'Ivoire. J Infect Dis 2003;187:20614.
  • 9
    Huang Y, Paxton WA, Wolinsky SM et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:12403.
  • 10
    Hraber P, Seaman MS, Bailer RT, Mascola JR, Montefiori DC, Korber BT. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 2014;28:1639.
  • 11
    Lindqvist M, van Lunzen J, Soghoian DZ et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest. 2012;122:327180.
  • 12
    Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC. Antibodies in HIV-1 vaccine development and therapy. Science 2013;341:1199204.
  • 13
    Simek MD, Rida W, Priddy FH et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009;83:733748.
  • 14
    Murphy MK, Yue L, Pan R et al. Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog 2013;9:e1003173.
  • 15
    Liao HX, Lynch R, Zhou T et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496:46976.
  • 16
    Klein F, Diskin R, Scheid JF et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013;153:12638.
  • 17
    Julien JP, Lee JH, Cupo A et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci USA 2013;110:43516.
  • 18
    Hessell AJ, Rakasz EG, Tehrani DM et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010;84:130213.
  • 19
    Huang J, Ofek G, Laub L et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012;491:40612.
  • 20
    Guenaga J, Wyatt RT. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function. PLoS Pathog 2012;8:e1002806.
  • 21
    McCoy LE, Weiss RA. Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med 2013;210:20923.
  • 22
    Munier CM, Andersen CR, Kelleher AD. HIV vaccines: progress to date. Drugs 2011;71:387414.
  • 23
    Baum LL. Role of humoral immunity in host defense against HIV. Curr HIV/AIDS Rep 2010;7:118.
  • 24
    Overbaugh J, Morris L. The Antibody Response against HIV-1. Cold Spring Harb Perspect Med. 2012;2:a007039.
  • 25
    Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 2009;4:38893.
  • 26
    Ampol S, Pattanapanyasat K, Sutthent R, Permpikul P, Kantakamalakul W. Comprehensive investigation of common antibody-dependent cell-mediated cytotoxicity antibody epitopes of HIV-1 CRF01_AE gp120. AIDS Res Hum Retroviruses 2012;28:12508.
  • 27
    Johnston MI, Fauci AS. HIV vaccine development–improving on natural immunity. N Engl J Med 2011;365:8735.
  • 28
    Ackerman M, Alter G. Mapping the journey to an HIV vaccine. N Engl J Med 2013;369:38991.
  • 29
    Moog C, Dereuddre-Bosquet N, Teillaud JL et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol 2014;7:4656.
  • 30
    Jain S, Rosenthal KL. The gp41 epitope, QARVLAVERY, is highly conserved and a potent inducer of IgA that neutralizes HIV-1 and inhibits viral transcytosis. Mucosal Immunol 2011;4:53953.
  • 31
    Hunt PW, Landay AL, Sinclair E et al. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS ONE 2011;6:e15924.
  • 32
    Ferrando-Martínez S, Casazza JP, Leal M et al. Differential Gag-specific polyfunctional T cell maturation patterns in HIV-1 elite controllers. J Virol 2012;86:366774.
  • 33
    Streeck H, D'Souza MP, Littman DR, Crotty S. Harnessing CD4⁺ T cell responses in HIV vaccine development. Nat Med 2013;19:1439.
  • 34
    International HIV Controllers Study. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010;330:15517.
  • 35
    Koup RA, Douek DC. Vaccine design for CD8 T lymphocyte responses. Cold Spring Harb Perspect Med 2011;1:a007252.
  • 36
    Ranasinghe SR, Kramer HB, Wright C et al. The antiviral efficacy of HIV-specific CD8⁺ T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate. PLoS Pathog 2011;7:e1001341.
  • 37
    Tenzer S, Wee E, Burgevin A et al. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol 2009;10:63646.
  • 38
    Zagury D, Salaün JJ, Bernard J, Dechazal L, Goussard B, Lurhuma Z. Immunization against the human immunodeficiency virus in Zaire. Med Trop (Mars) 1988;48:41723.
  • 39
    Esparza J. A brief history of the global effort to develop a preventive HIV vaccine. Vaccine 2013;31:350218.
  • 40
    Excler JL, Tomaras GD, Russell ND. Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS 2013;8:42030.
  • 41
  • 42
    Beena V, Choudhary K, Rajeev R, Sivakumar R, Heera R, Padmakumar S. Human immunodeficiency virus vaccine an update. J Oral Maxillofac Pathol 2013;17:7681.
  • 43
    Saunders KO, Rudicell RS, Nabel GJ. The design and evaluation of HIV-1 vaccines. AIDS 2012;26:1293302.
  • 44
    De Gregorio E, Caproni E, Ulmer JB. Vaccine adjuvants: mode of action. Front Immunol 2013;4:214.
  • 45
    García A, De Sanctis JB. An overview of adjuvant formulations and delivery systems. APMIS 2013;122:25767.
  • 46
    Stevceva L. Toll-like receptor agonists as adjuvants for HIV vaccines. Curr Med Chem 2011;18:507982.
  • 47
    Lind A, Brekke K, Sommerfelt M et al. Boosters of a therapeutic HIV-1 vaccine induce divergent T cell responses related to regulatory mechanisms. Vaccine 2013;31:46118.
  • 48
    Butler NS, Nolz JC, Harty JT. Immunologic considerations for generating memory CD8 T cells through vaccination. Cell Microbiol 2011;13:92533.
  • 49
    García F, Plana M, Climent N, León A, Gatell JM, Gallart T. Dendritic cell based vaccines for HIV infection: The way ahead. Hum Vaccin Immunother 2013;9:244552.
  • 50
    Chun TW, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 2012;26:12618.
  • 51
    van der Sluis RM, Jeeninga RE, Berkhout B. Establishment and molecular mechanisms of HIV-1 latency in T cells. Curr Opin Virol 2013;3:7006.
  • 52
    Santra S, Liao HX, Zhang R et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010;16:3248.
  • 53
    Barouch DH, O'Brien KL, Simmons NL et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010;16:31923.
  • 54
    Stephenson KE, Barouch DH. A global approach to HIV-1 vaccine development. Immunol Rev 2013;254:295304.
  • 55
    Bontjer I, Melchers M, Tong T et al. Comparative immunogenicity of evolved V1V2-deleted HIV-1 envelope glycoprotein trimers. PLoS ONE 2013;8:e67484.
  • 56
    Haynes BF, Gilbert PB, McElrath MJ et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366:127586.
  • 57
    Martin G, Burke B, Thaï R et al. Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic. J Biol Chem 2011;286:2170616.
  • 58
    Murphey-Corb M, Martin LN, Davison-Fairburn B et al. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 1989;246:12937.
  • 59
    Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992;258:193841.
  • 60
    Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, Desrosiers RC. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 1999;73:835663.
  • 61
    Blower SM, Koelle K, Kirschner DE, Mills J. Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety. Proc Natl Acad Sci USA 2001;98:361823.
  • 62
    Parks CL, Picker LJ, King CR. Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS 2013;8:40110.
  • 63
    Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191:65465.
  • 64
    O'Connell RJ, Kim JH, Corey L, Michael NL. Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med 2012;2:a007351.
  • 65
    Pitisuttithum P, Gilbert P, Gurwith M et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006;194:166171.
  • 66
    Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007;178:6596603.
  • 67
    Cheong C, Choi JH, Vitale L et al. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood 2010;116:382838.
  • 68
    Kumar D, Sharma D, Singh G, Singh M, Rathore MS. Lipoidal soft hybrid biocarriers of supramolecular construction for drug delivery. ISRN Pharm 2012;2012:474830.
  • 69
    Pastori C, Tudor D, Diomede L et al. Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41. Virology 2012;431:111.
  • 70
    García-Arriaza J, Arnáez P, Gómez CE, Sorzano CO, Esteban M. Improving adaptive and memory immune responses of an HIV/AIDS vaccine candidate MVA-B by deletion of vaccinia virus genes (C6L and K7R) blocking interferon signaling pathways. PLoS ONE. 2013;8:e66894.
  • 71
    Nascimento IP, Leite LC. Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Res 2012;45:110211.
  • 72
    Price PJ, Torres-Domínguez LE, Brandmüller C, Sutter G, Lehmann MH. Modified Vaccinia virus Ankara: Innate immune activation and induction of cellular signalling. Vaccine 2013;31:42314.
  • 73
  • 74
    D'Souza MP, Frahm N. Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies. AIDS 2010;24:8039.
  • 75
    Johnson JA, Barouch DH, Baden LR. Nonreplicating vectors in HIV vaccines. Curr Opin HIV AIDS 2013;8:4119.
  • 76
    McElrath MJ, De Rosa SC, Moodie Z et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008;372:1894905.
  • 77
    Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:188193.
  • 78
    O'Brien KL, Liu J, King SL et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009;15:8735.
  • 79
    Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010;5:35761.
  • 80
    Masek-Hammerman K, Li H, Liu J et al. Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5. J Virol 2010;84:98106.
  • 81
    Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:220920.
  • 82
  • 83
    de Souza MS, Ratto-Kim S, Chuenarom W et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 2012;188:516676.
  • 84
    Vaccari M, Poonam P, Franchini G. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev Vaccines 2010;9:9971005.
  • 85
    Liu P, Yates NL, Shen X et al. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccines. J Virol 2013;87:782836.
  • 86
    Girard MP, Osmanov S, Assossou OM, Kieny MP. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine 2011;29:6191218.
  • 87
    Madhavi V, Kent SJ, Stratov I. HIV-specific antibody-dependent cellular cytotoxicity: a novel vaccine modality. Expert Rev Clin Immunol 2012;8:76774.
  • 88
    Haynes BF, McElrath MJ. Progress in HIV-1 vaccine development. Curr Opin HIV AIDS 2013;8:32632.
  • 89
    Coban C, Kobiyama K, Jounai N, Tozuka M, Ishii KJ. DNA vaccines: A simple DNA sensing matter? Hum Vaccin Immunother. 2013;9: 221621.
  • 90
    Kalams SA, Parker SD, Elizaga M et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 2013;208:81829.
  • 91
    Zhou J, Cheung AK, Tan Z et al. PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice. J Clin Invest 2013;123:262942.
  • 92
    Liu L, Qiu C, Huang Y, Xu J, Shao Y. Potent T cell responses induced by single DNA vaccine boosted with recombinant vaccinia vaccine. Virol Sin 2013;28:10915.
  • 93
    Li M, Jiang Y, Xu C, Zhang Z, Sun X. Enhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant. Int J Nanomedicine 2013;8:184354.
  • 94
    Li J, Valentin A, Kulkarni V et al. HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine 2013;31:374755.
  • 95
    Hammer SM, Sobieszczyk ME, Janes H et al. Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. N Engl J Med. 2013; 369: 208392.
  • 96
    Henriksen-Lacey M, Bramwell VW, Christensen D, Agger EM, Andersen P, Perrie Y. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J Control Release 2010;142:1806.
  • 97
    Watson DS, Endsley AN, Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immuneresponses to liposome associated antigens. Vaccine 2012;30:225672.
  • 98
    Bomsel M, Tudor D, Drillet AS et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011;34:26980.
  • 99
    Brunner R, Jensen-Jarolim E, Pali-Schöll I. The ABC of clinical and experimental adjuvants–a brief overview. Immunol Lett 2010;128:2935.
  • 100
    Launay O, Surenaud M, Desaint C et al. Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine 2013;31:440615.
  • 101
    Visciano ML, Tagliamonte M, Stewart-Jones G et al. Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate. J Transl Med 2013;11:165.
  • 102
    Horton RE, Vidarsson G. Antibodies and their receptors: different potential roles in mucosal defense. Front Immunol 2013;4:200.
  • 103
    Manrique M, Kozlowski PA, Cobo-Molinos A et al. Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes. J Virol 2013;87:473850.
  • 104
    Sircar P, Furr KL, Letvin NL. Systemic vaccination induces clonally diverse SIV-specific CD8+ T-cell populations in systemic and mucosal compartments. Mucosal Immunol 2013;6:93103.
  • 105
    Ranasinghe C, Trivedi S, Stambas J, Jackson RJ. Unique IL-13Rα2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8(+) T-cell avidity and protective immunity. Mucosal Immunol 2013;6:106880.
  • 106
    Leroux-Roels G, Maes C, Clement F et al. Randomized phase I: safety, immunogenicity and mucosal antiviral activity in young healthy women vaccinated with HIV-1 Gp41 P1 peptide on virosomes. PLoS ONE 2013;8:e55438.
  • 107
    Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine development. Annu Rev Med 2012;63:95111.